Non‐Engineered Physiologically Modulated Nanovesicles Augment Antitumor Immune Responses via Dual‐Pathway T Cell Activation

T cells through both antigen self-presentation and dendritic cell-mediated antigen presentation, ultimately eliciting robust immune responses. This non-engineered, physiologically modulated nanovaccine exhibits broad-spectrum antitumor activity while simultaneously inducing durable systemic immune memory to effectively suppress tumor recurrence and metastasis. Overall, the ASCENT nanovaccine provides new perspectives on rational vaccine design, emphasizing the importance of engaging both direct and indirect T cell activation in reinforcing cancer immunotherapy.